Terry Chrisomalis
Contributor since: 2013
Company: Biotech analysis central through seeking alpha
Latest Articles
CymaBay Reinforces Its Efforts With Latest Rare Liver Disease Data
Viking Shows Potential Competitive Advantage In NASH Space
Biotech Analysis Central Pharma News: Merrimack's Struggle, Eli Lilly's Setback, Amarin's Issue
Biotech Analysis Central Pharma News: Voyager's Update, Sarepta's Raise, Nektar's Struggle
Biotech Analysis Central Pharma News: Johnson & Johnson's Partnership, Dynavax's Advancements, Aveo's Positive Results
Biotech Analysis Central Pharma News: Gilead's Push, AcelRx's Approval, Trevena's Rejection
Pfizer Wants To Get On Top In The NASH Space With The Combination Approach
Dicerna Pharmaceuticals Keeps The Deals Rolling In On The Promise Of Its Groundbreaking GalXC RNAi Technology
Regeneron's Latest CRL Is Just A Minor Inconvenience That Can Be Dealt With Quickly
Dynavax's Melanoma Results May Be The Next Step To Its Evolution
Ultragenyx Fails Trial, But Its Long-Term Track Can't Be Dismissed
AstraZeneca Lynparza Scores A Big Win At ESMO
Merrimack Fails Mid-Stage Study, But 2 Shots On Goal May Help It Redeem Itself
Proteostasis Therapeutics Surges On Cystic Fibrosis Data, Can The Run Continue?
Novartis Bolts On New Radioligand Therapy For Treating Prostate Cancer
Biotech Analysis Central Pharma News: Regeneron's Results, Bristol-Myers' Failure, Novartis' FDA Rejection
Biotech Analysis Central Pharma News: Roche's Deal, AcelRX Panel Vote, Crispr And Vertex Hold Removal
Biotech Analysis Central Pharma News: Menlo's Failure, Trevena's Documents, Affimed Halts Studies
Novartis Looks To Maintain Market Strength In Multiple Sclerosis Space
Aduro Tanks On J&J Partnership Termination Surprise, But Others Remain In Place
Arrowhead Surges Forward With Major Deal And Its Intentions Were Highly Misunderstood
Regeneron Achieves An FDA First With Immunotherapy Cancer Product
Eli Lilly Looks To Be A Strong Competitor In The Preventative Migraine Market
Pfizer Snatches FDA Approval For Rare Front-Line Lung Cancer Indication
Biotech Analysis Central Pharma News: Gilead's New Move, Sarepta's Hold Removal, Alexion's Plan
Amarin's Vascepa Outcome Marks A Key Turnaround Event
Verastem Tackles FDA Approval For Blood Cancer Drug
Acadia Receives A Rubber Stamp From FDA On Nuplazid Risk-Benefit Profile
Mersana Gets Clinical Hold Lifted, But Is Not Met With Welcomed Arms
Viking Is A Biotech With Massive Potential
Allergan Snaps Up Early Stage Startup, Goes Back To Its Aesthetic Roots
AstraZeneca Receives FDA Approval For Rare B-Cell Lymphoma Drug Lumoxiti